Entity

Time filter

Source Type

Dublin, Ireland

RCSI , is an elite Dublin-based medical institution, situated on St. Stephen's Green. The college is one of the five Recognised Colleges of the National University of Ireland. The college dates back to 1784 and at present incorporates schools of medicine, pharmacy, physiotherapy and nursing, providing both undergraduate and postgraduate levels of medical education.Among medical institutions outside Ireland, the use of the term "Royal College" currently indicates an oversight body for postgraduate medical education. RCSI performs such a function, but it is unique among the four Royal Colleges of Surgeons in that 100 years after its establishment, an undergraduate medical school was founded and this is now Ireland's largest medical school with over 3000 students from 60 countries. The RCSI is a sister institute of the Royal Surgical Colleges of the United Kingdom . Wikipedia.


A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumour sample from the patient for expression of ADAM22, wherein expression of ADAM22 correlates with increased potential for metastasis compared with a patient who is ADAM22 negative. The invention also describes an agent for use in the treatment of metastatic breast cancer in a patient, in which the agent is selected from LGI1 protein (SEQ ID NO:1) and an LGI1 peptide mimic capable of mimicking the ADAM22 binding activity of LGI1 by binding to the LGI1 binding domain of ADAM22 (SEQ ID NO: 4) and which is capable of inhibiting migration of endocrine resistant breast cancer cells.


Patent
Royal College of Surgeons in Ireland | Date: 2013-06-26

The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.


Patent
Royal College of Surgeons in Ireland | Date: 2015-05-29

The invention relates to a method for producing a multi-layer collagen scaffold. The method generally comprises the steps of: preparing a first suspension of collagen and freezing or lyophilising the suspension to provide a first layer; optionally preparing a further suspension of collagen and adding the further suspension onto the layer formed in the previous step to form a further layer, and freezing or lyophilising the layers, wherein when the layer formed in the previous step is formed by lyophilisation the lyophilised layer is re-hydrated prior to addition of the next layer; optionally, repeating the aforementioned step to form one or more further layers; and preparing a final suspension of collagen and pouring the final suspension onto the uppermost layer to form a final layer, and freeze-drying the layers to form the multi-layer collagen composite scaffold.


Patent
Royal College of Surgeons in Ireland | Date: 2013-03-06

A process for producing a collagen/hydroxyapatite (HA) composite scaffold comprises the steps of forming a homogenous suspension of collagen and HA in an acidic solution, lyophilising the suspension until a desired final freezing temperature is reached to produce the composite scaffold, and optionally cross-linking the composite scaffold, wherein the ratio of HA to collagen is at least 1:10 (w/w). Also provided is a collagen/hydroxyapatite (HA) composite scaffold comprising a homogenous distribution of hydroxyapatite within a porous, crosslinked, collagen matrix, wherein the ratio of HA to collagen is at least 1:10 (w/w). Suitably, the composite scaffold has a porosity of at least 99% (v/v), and a compressive stiffness of at least 0.3 KPa. Composite scaffolds of the invention may be used to provide osteoconductive bone implants and tissue engineering implants.


Patent
Royal College of Surgeons in Ireland | Date: 2012-09-28

A method for preventing or treating epilepsy or status epilepticus, or a brain-related disorder characterised by precipitation of seizures, in an individual, the method comprising the step of treating the individual with an agent capable of inhibiting the activity of miR-134 in the individual, wherein the agent is delivered to the brain of the individual.

Discover hidden collaborations